Ricardo Colacioppo, MD
Cardiovascular Disease · San Juan, PRNPI 1023217775
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,560 of the $13,691 with a category attached, or 77.1%. 23 manufacturers reported payments, led by AstraZeneca at 28.6% of the total. Reporting peaked in 2020 at $3,236 and has fallen 64.2% since, to $1,159 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $61.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Boehringer Ingelheim$2K
- Amgen$1K
- Boston Scientific$1K
- Johnson & Johnson$832
- E.r. Squibb & Sons, L.L.C.$813
- plus $4K from 17 others
What the payments were for
- Speaking & faculty fees$3,10023%
- Food & beverage$10,56077%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $3,911 |
| Boehringer Ingelheim | 37 | $2,000 |
| Amgen | 24 | $1,354 |
| Boston Scientific | 13 | $1,247 |
| Johnson & Johnson | 22 | $832 |
| E.r. Squibb & Sons, L.L.C. | 22 | $813 |
| Abbott | 10 | $800 |
| PBG Puerto Rico LLC | 22 | $462 |
| Merck | 13 | $406 |
| Medtronic(2 entities) | 3 | $363 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $363 |
| Pfizer Pharmaceuticals LLC | 4 | $339 |
| Lilly USA, LLC | 2 | $237 |
| Novo Nordisk | 2 | $148 |
| Bayer | 1 | $125 |
| Edwards Lifesciences | 1 | $115 |
| Bayer Puerto Rico Inc. | 2 | $50 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $25 |
| Biotronik Inc. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Pfizer | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$3,462
- JARDIANCE$1,338
- Repatha$955
- WATCHMAN FLX$470
- ELIQUIS$344
- EMBLEM MRI S-ICD$264
- ZEPBOUND$237
- UNIFY ASSURA$221
- XARELTO$214
- LifeVest$200
- LUX-Dx Insertable Cardiac Monitor$144
- CARDIOBLATE CRYOFLEX$140
- NA$136
- Ozempic$125
- GALLANT$117
- BRILINTA$105
- Unify Assura CRT Defibrillator$104
- Watchman$104
- ENSITE PRECISION$102
- STEGLATRO$100
How this compares
$13,691 in reported general payments places this provider in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 444 | $324,904 |
| FarxigaDapagliflozin Propanediol | 240 | $176,357 |
| XareltoRivaroxaban | 189 | $144,254 |
| EntrestoSacubitril/Valsartan | 109 | $96,490 |
| JanuviaSitagliptin Phosphate | 58 | $42,008 |
| JardianceEmpagliflozin | 54 | $41,675 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $41,634 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $33,273 |
| Candesartan Cilexetil | 387 | $32,115 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 44 | $28,165 |
| SynthroidLevothyroxine Sodium | 380 | $25,273 |
| BrilintaTicagrelor | 44 | $22,315 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $18,174 |
| TradjentaLinagliptin | 19 | $17,996 |
| Repatha SureclickEvolocumab | 29 | $16,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $8 | $324,904444 claims |
| AstraZenecaFarxiga, Brilinta | $3,911 | $198,672284 claims |
| Johnson & JohnsonXarelto | $832 | $144,254189 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy, Glyxambi | $2,000 | $125,318171 claims |
| MerckJanuvia, Janumet, Janumet Xr | $406 | $93,455136 claims |
| Novo NordiskOzempic | $148 | $16,20617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in San Juan
- Manuel GuzmanSan Juan$203K
- Ramon PereaSan Juan$68K
- Francisco Merced-OrtizSan Juan$54K
- Sonia VicentySan Juan$23K
- Sonia Velazquez-NavarroSan Juan$17K
- Pedro Vargas-OteroSan Juan$15K
- Jose Kareh CorderoSan Juan$13K
- William Borges CancelSan Juan$13K
- Zuanette Ramos-RoblesSan Juan$13K
- Edwin Rodriguez CruzSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.